Interesting Engineering on MSN13d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
Managed Healthcare Executive12d
FDA Approves First Biosimilar of Novolog
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
BioPharma Dive7d
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Drug Store News12d
Sanofi nears selling 50% controlling stake in Opella to CD&R
Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...
Sanofi India shares rise 4% on strong topline and operational show, net profit sharply lower
Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.
cnbctv184d
Sanofi India Q4 revenue, EBITDA rise; ₹117 final dividend recommended
Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...